Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer
Active, not recruiting · Phase 1 · NCT05633979
Conditions: Breast Cancer
At a glance
- Research payments reported, 2025
- $2.7M
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 17
About the trial
- Sponsor
- M.D. Anderson Cancer Center (with Daiichi Sankyo)
- Tested
- Trastuzumab deruxtecan (drug), Valemetostat (drug)
- Dates
- Started 2023-02-09; completion 2032-12-31
- Results posted
- Not yet
To find a recommended dose of valemetostat that can be given in combination with trastuzumab deruxtecan to patients with low/ultra-low HER2-expressing metastatic breast cancer.
From ClinicalTrials.gov, last updated 2026-07-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $2.7M in research payments for this study in 2025 (4 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ut MD Anderson Cancer Center $2.7M
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.